TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

In Section C, participants will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until finally disease progression or perhaps the contributors are not able to tolerate the study drugs.Achievable new methods for your analysis and treatment of AML. (A) The identification o